{"type":"trials","record":{"id":41411,"source_id":"clinicaltrials-gov","external_id":"NCT07744204","title":"LEAP Strategy for Neovascular Age-Related Macular Degeneration","brief_summary":"Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The \"wet\" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and leak fluid. The current standard treatment requires repeated eye injections of anti-VEGF drugs, often every month or every few months. This frequent injection schedule is a heavy burden for patients and many cannot keep up with the treatment plan. Purpose: This study tests whether a single session of low-intensity laser applied to the diseased area, given just before the anti-VEGF injection, can help the drug reach the target more effectively. If this works, patients may need far fewer injections over time. Intervention: Participants will be randomly assigned to one of two groups. The experimental group will receive the laser treatment followed by an anti-VEGF injection within 6 hours. The control group will receive the anti-VEGF injection alone, according to the current standard regimen. Four different anti-VEGF drugs are allowed in this study: conbercept, aflibercept, ranibizumab, and faricimab. Participants: The study plans to enroll at least 240 patients with active neovascular AMD across five hospitals in China. All participants must be at least 50 years old and meet specific eligibility criteria. Follow-up: All participants will be followed for 24 months with monthly clinic visits. The study will record the total number of injections received, changes in vision, fluid status on eye scans, and any side effects. Primary Outcome: The main measure is the total number of anti-VEGF injections each participant needs over the 24-month period. The study will compare the experimental group and the control group to see whether the laser-enhanced approach reduces the injection frequency.","overall_status":"Not Yet Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Chinese PLA General Hospital","enrollment":240,"countries":[],"start_date":"2026-08-01","completion_date":"2029-07-31","last_update_date":"2026-08-19","source_url":"https://clinicaltrials.gov/study/NCT07744204","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"LEAP","age_range":"50 Years to 99 Years","comparator":"Conventional Treatment Group","organization":"Chinese PLA General Hospital","interventions":["Laser photocoagulation","Anti-VEGF agents"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Total Number of Anti-VEGF Injections Over 24 Months — 24 months","Change in Best-Corrected Visual Acuity — Baseline to 24 months","Incidence of Subretinal or Intraretinal Fluid — 24 months","Total Number of Injections by Drug Subgroup — 24 months","Change in NEI-VFQ-25 Composite Score — Baseline to 24 months","Change in EQ-5D-5L Utility Index — Baseline to 24 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration(nAMD)","Wet Macular Degeneration","Laser photocoagulation","Anti-VEGF agents"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07744204","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-08-01 to 2029-07-31","comparator":"Conventional Treatment Group","confidence":"structured-source","population":"ALL · 50 Years to 99 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.807Z","intervention":["Laser photocoagulation","Anti-VEGF agents"],"participants":240,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Total Number of Anti-VEGF Injections Over 24 Months — 24 months","Change in Best-Corrected Visual Acuity — Baseline to 24 months","Incidence of Subretinal or Intraretinal Fluid — 24 months","Total Number of Injections by Drug Subgroup — 24 months","Change in NEI-VFQ-25 Composite Score — Baseline to 24 months","Change in EQ-5D-5L Utility Index — Baseline to 24 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41411","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}